Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R)

Neuropeptides

Volumn 41, Issue 4, 2007, Pages 195-205

  Vasiliou, A S ^a   MacKenzie, A ^b   Morris, R ^a   McLaughlin, L ^a   Bubb, V J ^a   Haddley, K ^a   Quinn, J P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anxiety; NK1R; Substance P; Tachykinins; Transgenic; YAC

Indexed keywords

ANTIBODY; GREEN FLUORESCENT PROTEIN; NEUROKININ 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DNA FLANKING REGION; FLUORESCENCE; GENE EXPRESSION; GENE LOCUS; HIPPOCAMPUS; INTERNAL RIBOSOME ENTRY SITE; LUNG DEAD SPACE; MARKER GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUTAMEN; TRANSGENE; TRANSGENIC MOUSE; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; CHROMOSOMES, ARTIFICIAL; GREEN FLUORESCENT PROTEINS; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; RECEPTORS, NEUROKININ-1; SPINAL CORD; TRANSGENES;

EID: 34347330145     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2007.04.005     Document Type: Article

References (41)

1. Acsady L., Katona I., Gulyas A.I., Shigemoto R., and Freund T.F. Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J. Comp. Neurol. 378 (1997) 320-336
2. Bannon M.J., and Whitty C.J. Neurokinin receptor gene-expression in substantia-Nigra - localization, regulation, and potential physiological significance. Can. J. Physiol. Pharmacol. 73 (1995) 866-870
3. Brown J.L., Liu H., Maggio J.E., Vigna S.R., Mantyh P.W., and Basbaum A.I. Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J. Comp. Neurol. 356 (1995) 327-344
4. Caberloto L., Hurd Y.L., Murdock P., Wahlin J.P., Melotto S., Corsi M., and Carletti R. Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain. Eur. J. Neurosci. 17 (2003) 1736-1746
5. Casini G., Brecha N.C., Bosco L., and Rickman D.W. Developmental expression of neurokinin-1 and neurokinin-3 receptors in the rat retina. J. Comp. Neurol. 421 (2000) 275-287
6. Casini G., Dal Monte M., Fornai F., Bosco L., Willems D., Yang Q., Zhou Z.J., and Bagnoli P. Neurokinin 1 receptor expression and substance P physiological actions are developmentally regulated in the rabbit retina. Neuroscience 124 (2004) 147-160
7. Catalani E., Dal Monte M., Gangitano C., Lucattelli M., Finischi S., Bosco L., Bagnoli P., and Casini G. Expression of substance P, neurokinin 1 receptors (NK1) and neurokinin 3 receptors in the developing mouse retina and in the retina of NK1 knockout mice. Neuroscience 138 (2006) 487-499
8. Conley R.K., Cumberbatch M.J., Mason G.S., Williamson D.J., Harrison T., Locker K., Swain C., Maubach K., O'Donnell R., Rigby M., et al. Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. 22 (2002) 7730-7736
9. Czeh B., Fuchs E., and Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opin. Investig. Drugs 15 (2006) 479-486
10. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J., Laird J.M., Belmonte C., Cervero F., and Hunt S.P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P [see comments]. Nature 392 (1998) 394-397
11. Fiskerstrand C.E., Lovejoy E.A., and Quinn J.P. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett. 458 2 (1999) 171-174
12. Gadd C.A., Murtra P., De Felipe C., and Hunt S.P. Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J. Neurosci. 23 (2003) 8271-8280
13. Giraldo P., and Montoliu L. Size matters: Use of YACs, BACs and PACs in transgenic animals. Transgenic Res. 10 (2001) 83-103
14. Hammock E.A., and Young L.J. Variation in the vasopressin V1a receptor promoter and expression: implications for inter- and intraspecific variation in social behaviour. Eur. J. Neurosci. 16 (2002) 399-402
15. Hogan B., Beddington R., Constantini F., and Lacy E. Manipulating the Mouse Embryo (1995), Cold Spring Harbor Laboratory Press, New York
16. Hopkins B., Powell S.J., Danks P., Briggs I., and Graham A. Isolation and characterisation of the human lung NK-1 receptor cDNA. Biochem. Biophys. Res. Commun. 180 (1991) 1110-1117
17. Huxley C. Exploring gene function: use of yeast artificial chromosome transgenesis. Methods 14 (1998) 199-210
18. Klenova E., Scott A.C., Roberts J., Shamsuddin S., Lovejoy E.A., Bergmann S., Bubb V.J., Royer H.D., and Quinn J.P. YB-1 and CTCF differentially regulate the 5-HTT polymorphic intron 2 enhancer which predisposes to a variety of neurological disorders. J. Neurosci. 24 (2004) 5966-5973
19. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors [see comments]. Science 281 (1998) 1640-1645
20. Laird J.M., Olivar T., Roza C., De Felipe C., Hunt S.P., and Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 98 (2000) 345-352
21. Lamb B.T., and Gearhart J.D. YAC transgenics and the study of genetics and human disease. Curr. Opin. Genet. Dev. 5 (1995) 342-348
22. Lee C.M., Campbell N.J., Williams B.J., and Iversen L.L. Multiple tachykinin binding sites in peripheral tissues and brain. Eur. J. Pharmacol. 130 (1986) 209-217
23. Li J.L., Ding Y.Q., Xiong K.H., Li J.S., Shigemoto R., and Mizuno N. Substance P receptor (NK1)-immunoreactive neurons projecting to the periaqueductal gray: distribution in the spinal trigeminal nucleus and the spinal cord of the rat. Neurosci. Res. 30 (1998) 219-225
24. Llewellyn-Smith I.J., Martin C.L., Minson J.B., Pilowsky P.M., Arnolda L.F., Basbaum A.I., and Chalmers J.P. Neurokinin-1 receptor-immunoreactive sympathetic preganglionic neurons: target specificity and ultrastructure. Neuroscience 77 (1997) 1137-1149
25. Lovejoy E.A., Scott A.C., Fiskerstrand C.E., Bubb V.J., and Quinn J.P. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur. J. Neurosci. 17 2 (2003) 417-420
26. MacKenzie A., and Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc. Natl. Acad. Sci. USA 96 (1999) 15251-15255
27. MacKenzie A., and Quinn J. A yeast artificial chromosome containing the human preprotachykinin - a gene expresses substance P in mice and drives appropriate marker-gene expression during early brain embryogenesis. Mol. Cell Neurosci. 19 (2002) 72-87
28. MacKenzie A., and Quinn J.P. Post genomic approaches to exploring neuropeptide gene mis-expression in disease. Neuropeptides 38 (2004) 1-15
29. MacKenzie A., Payne C., Boyle S., Clarke A.R., and Quinn J.P. The human preprotachykinin - a gene promoter has been highly conserved and can drive human-like marker gene expression in the adult mouse CNS. Mol. Cell Neurosci. 16 (2000) 620-630
30. Maggi C.A. Tachykinin receptors and airway pathophysiology. Eur. Respir. J. 6 (1993) 735-742
31. Maggio J.E. Tachykinins. Annu. Rev. Neurosci. 11 (1988) 13-28
32. Mantyh P.W., Gates T., Mantyh C.R., and Maggio J.E. Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J. Neurosci. 19 (1989) 258-279
33. Martin J.L., and Sloviter R.S. Focal inhibitory interneuron loss and principal cell hyperexcitability in the rat hippocampus after microinjection of a neurotoxic conjugate of saporin and a peptidase-resistant analog of substance P. J. Comp. Neurol. 436 (2001) 127-152
34. Maubach K.A., Martin K., Chicchi G., Harrison T., Wheeldon A., Swain C.J., Cumberbatch M.J., Rupniak N.M., and Seabrook G.R. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 109 (2002) 609-617
35. Quartara L., and Maggi C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 32 (1998) 1-49
36. Rigby M., O'Donnell R., and Rupniak N.M. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J. Comp. Neurol. 490 (2005) 335-353
37. Rupniak N.M. New insights into the antidepressant actions of substance P (NK1 receptor) antagonists. Can. J. Physiol. Pharmacol. 80 (2002) 489-494
38. Schedl A., Montoliu L., Kelsey G., and Schutz G. A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice. Nature 362 (1993) 258-261
39. Schedl A., Grimes B., and Monoliu L. YAC transfer by microinjection. In: Markie D. (Ed). YAC Protocols (1996), Humana Press Inc, Totowa, NJ
40. Whitty C.J., Walker P.D., Goebel D.J., Poosch M.S., and Bannon M.J. Quantitation, cellular-localization and regulation of neurokinin receptor gene-expression within the rat substantia-Nigra. Neuroscience 64 (1995) 419-425
41. Zimmer A., Zimmer A.M., Baffi J., Usdin T., Reynolds K., Konig M., Palkovits M., and Mezey E. Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc. Natl. Acad. Sci. USA 95 (1998) 2630-2635